Coherus BioSciences General and Administrative Expenses 2011-2026 | CHRS

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Coherus BioSciences

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
192 M	198 M	170 M	139 M	137 M	94.2 M	71.3 M	51.6 M	36 M	17.6 M	7.46 M	5.53 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
198 M	5.53 M	93.3 M

Quarterly General and Administrative Expenses Coherus BioSciences

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
24.9 M	26 M	26 M	-	28.1 M	27.5 M	40.2 M	-	48.2 M	45.1 M	49.2 M	-	44.8 M	51.3 M	48.8 M	-	39.9 M	40.3 M	39.4 M	-	32 M	34.1 M	35.4 M	-	31.8 M	36.5 M	32.7 M	-	25.4 M	18.4 M	16.6 M	-	14 M	23.5 M	18.8 M	-	13.6 M	11.3 M	11.4 M	-	10.2 M	8.82 M	6.09 M	-	3.98 M	3.98 M	3.42 M	-	2.36 M	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
51.3 M	2.36 M	26.3 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
AgeX Therapeutics AGE	9.33 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	45.8 M	-	-	$ 1.01 B	USA
Adagene ADAG	14.4 M	$ 1.65	7.91 %	$ 92.9 M	China
Alterity Therapeutics Limited ATHE	5.51 M	$ 3.59	1.99 %	$ 8.64 B	Australia
Arrowhead Pharmaceuticals ARWR	124 M	$ 66.05	2.3 %	$ 8.83 B	USA
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Autolus Therapeutics plc AUTL	46.7 M	$ 1.52	-16.3 %	$ 388 M	Britain
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
Akero Therapeutics AKRO	37.9 M	-	-	$ 3.67 B	USA
Biogen BIIB	2.4 B	$ 184.48	-1.67 %	$ 26.9 B	USA
AVROBIO AVRO	24 M	-	1083.1 %	$ 745 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
BioNTech SE BNTX	286 M	$ 102.17	2.32 %	$ 27.2 B	Germany
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
AstraZeneca PLC AZN	15.2 B	$ 93.52	-1.2 %	$ 96.9 B	Britain
Can-Fite BioPharma Ltd. CANF	3.05 M	$ 4.25	1.67 %	$ 9.25 B	Israel
BeiGene, Ltd. BGNE	1.83 B	-	0.49 %	$ 251 B	Cayman-islands
Bellicum Pharmaceuticals BLCM	5.72 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	95.1 M	-	-7.31 %	$ 87 M	USA
Bristol-Myers Squibb Company BMY	8.41 B	$ 55.71	-0.28 %	$ 113 B	USA
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
Ascendis Pharma A/S ASND	160 M	$ 207.49	2.22 %	$ 5 B	Danmark
Codiak BioSciences CDAK	27.6 M	-	-55.98 %	$ 2.15 M	USA
ARCA biopharma ABIO	13.1 M	-	1052.0 %	$ 415 M	USA
Cerevel Therapeutics Holdings CERE	113 M	-	-	$ 7.29 B	USA
Acasti Pharma ACST	7.17 M	-	4.01 %	$ 150 M	Canada
Zai Lab Limited ZLAB	299 M	$ 18.37	-0.97 %	$ 18.2 B	China
Catalyst Biosciences CBIO	14.7 M	$ 10.84	0.46 %	$ 714 M	USA
Caladrius Biosciences CLBS	12.1 M	-	-16.75 %	$ 25.8 M	USA
Celldex Therapeutics CLDX	38.5 M	$ 25.59	-6.54 %	$ 1.65 M	USA
Cellectis S.A. CLLS	37.9 M	$ 4.22	-4.2 %	$ 116 M	France
Clearside Biomedical CLSD	11.9 M	-	-	$ 25.3 M	USA
Chimerix CMRX	24.6 M	-	-	$ 756 M	USA
Adaptimmune Therapeutics plc ADAP	73.5 M	-	-15.15 %	$ 60.3 M	Britain
Corcept Therapeutics Incorporated CORT	280 M	$ 37.35	-0.4 %	$ 3.86 B	USA
Catalyst Pharmaceuticals CPRX	59 M	$ 23.18	2.02 %	$ 2.75 B	USA
AIkido Pharma AIKI	29.7 M	-	1.93 %	$ 17.4 M	USA
Albireo Pharma ALBO	69.6 M	-	-0.23 %	$ 916 M	USA
CureVac N.V. CVAC	100 M	-	-	$ 867 M	Germany
Acer Therapeutics ACER	12.7 M	-	2.71 %	$ 14 M	USA
Alpine Immune Sciences ALPN	18 M	-	-	$ 2.17 B	USA
AlloVir ALVR	42.9 M	-	4.14 %	$ 49.1 M	USA
Crinetics Pharmaceuticals CRNX	99.7 M	$ 55.11	3.49 %	$ 4.45 B	USA
CRISPR Therapeutics AG CRSP	73 M	$ 55.17	2.47 %	$ 4.65 B	Schweiz
Ayala Pharmaceuticals AYLA	1.53 M	-	-	$ 7.46 M	Israel
Zentalis Pharmaceuticals ZNTL	64.4 M	$ 3.53	-5.75 %	$ 231 M	USA
Ampio Pharmaceuticals AMPE	7.08 M	-	-11.43 %	$ 502 K	USA
Amphastar Pharmaceuticals AMPH	56.7 M	$ 29.43	6.09 %	$ 1.43 B	USA